Skip to main content

View full-text article in PMC

. 2011 May 25;2:317–323. doi: 10.7150/jca.2.317

Table 2.

Results of clinical trials

CLINICAL TRIALS
Slamon DJ et al. ¹⁵	METASTATIC BREAST CANCER	CT alone	20.1 median OS	p=0,046
Slamon DJ et al. ¹⁵	METASTATIC BREAST CANCER	CT plus Trastuzumab	25.1 median OS	p=0,046
Romond EH et al. ¹⁶	EARLY STAGES LOCALLY INVASIVE BREAST CANCER	CT alone	86.6% OS at 4 years	p=0,015
Romond EH et al. ¹⁶		CT plus Trastuzumab	91.4% OS at 4 years	p=0,015
Piccart-Gebhart MJ et al. ¹⁷		CT alone	95.1% OS at 2 years	p=0,26
Piccart-Gebhart MJ et al. ¹⁷		CT plus Trastuzumab	96% OS at 2 years	p=0,26
Smith I et al. ¹⁸		CT alone	89.4% OS at 2 years	p=0,005
Smith I et al. ¹⁸		CT plus Trastuzumab	92.4% at 2 years	p=0,005

OS=overall survival